RE ENDOTHELIALIZATION AND RESTENOSIS

再内皮化和再狭窄

• 批准号: 2609392
• 负责人: Jeffrey Isner
• 金额: $ 28.15万
• 依托单位: STEWARD ST. ELIZABETH'S MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2609392
• 关键词: angiogenesis; angiography; cell growth regulation; cell proliferation; hyperlipidemia; immunocytochemistry; intraluminal angioplasty; laboratory mouse; laboratory rabbit; laboratory rat; mitogens; muscle tone; nitric oxide; northern blottings; regeneration; restenosis; transfection /expression vector; vascular endothelial growth factors; vascular endothelium; western blottings

DESCRIPTION (adapted from the applicant's abstract): The hypotheses to be tested in each case have been organized according to the following three Specific Aims. Specific Aim #1: To investigate the potential for endothelial cell (EC) mitogens to accelerate re-endothelialization (rET); Specific Aim #2: To investigate certain mechanisms by which EC mitogens facilitate rET; and Specific Aim #3: To investigate augmented rET using EC precursors isolated from peripheral blood. The studies will be performed in vitro and in vivo. The latter will include a hyperlipidemic rabbit model of double-balloon injury, and, in selected cases, rat and mouse models of single and/or double-balloon injury. Experiments in Specific Aim #1 are expected to define, short of human studies, the potential for EC mitogens to effectively modulate pathologic alteration of the artery wall. Experiments from Specific Aim #2 are expected to elucidate the role of vascular endothelial growth factor (VEGF) as a previously unappreciated endogenous regulatory factor responsible for maintaining and restoring the integrity of the vascular endothelium. Experiments form Specific Aim 3 are considered by the applicant to constitute a "supply side" strategy that will consider circulating EC precursors as penultimate ECs that may be used in conjunction with EC mitogens to augment rET.

描述（改编自申请人的摘要）：假设为 在每种情况下都根据以下三个进行了测试 具体目标。 特定目的＃1：调查潜力 内皮细胞（EC）有丝分裂剂加速再内皮化（RET）； 特定目的＃2：调查某些EC有丝菌的机制 促进RET；和特定目标＃3：使用EC调查增强RET 从外周血分离的前体。 研究将在 体内和体内。 后者将包括一个高脂兔模型 双球损伤，在选定的情况下，大鼠和小鼠模型 单球和/或双球损伤。 特定目标＃1中的实验是 预计将定义，缺乏人类研究，EC有丝分裂原的潜力 有效调节动脉壁的病理改变。 实验 从特定的目标＃2中有望阐明血管的作用 内皮生长因子（VEGF）作为先前未批准的内源性 负责维持和恢复完整性的监管因素 血管内皮。 特定目标3的实验由 构成“供应方面”策略的申请人将考虑 循环EC前体作为倒数第二个EC，可以结合使用 EC有丝分裂剂可增强RET。